Evidence map›Paper›PMID 34603483›Full record

ArticleComputational and mathematical methods in medicine2021

Identification of Novel COVID-19 Biomarkers by Multiple Feature Selection Strategies.

Shuai Zhang, Renliang Qu, Pengyan Wang, Shenghan Wang

Open access · hybridAbstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shuai ZhangDepartment of Clinical Laboratory, Yantai Qishan Hospital, Yantai, Shandong Province, China 264000.ORCID https://orcid.org/0000-0002-5824-7546
Renliang QuDepartment of Clinical Laboratory, Yantai Qishan Hospital, Yantai, Shandong Province, China 264000.ORCID https://orcid.org/0000-0002-2567-789X
Pengyan WangDepartment of Clinical Laboratory, Yantai Qishan Hospital, Yantai, Shandong Province, China 264000.ORCID https://orcid.org/0000-0002-0282-8536
Shenghan WangDepartment of Microbiological Laboratory, Yantai Zhifu Center for Disease Control and Prevention, Yantai, Shandong Province, China 264000.ORCID https://orcid.org/0000-0002-4472-3986
Yantaishan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) arising from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic since its first report in December 2019. So far, SARS-CoV-2 nucleic acid detection has been deemed as the golden standard of COVID-19 diagnosis. However, this detection method often leads to false negatives, thus triggering missed COVID-19 diagnosis. Therefore, it is urgent to find new biomarkers to increase the accuracy of COVID-19 diagnosis. To explore new biomarkers of COVID-19 in this study, expression profiles were firstly accessed from the GEO database. On this basis, 500 feature genes were screened by the minimum-redundancy maximum-relevancy (mRMR) feature selection method. Afterwards, the incremental feature selection (IFS) method was used to choose a classifier with the best performance from different feature gene-based support vector machine (SVM) classifiers. The corresponding 66 feature genes were set as the optimal feature genes. Lastly, the optimal feature genes were subjected to GO functional enrichment analysis, principal component analysis (PCA), and protein-protein interaction (PPI) network analysis. All in all, it was posited that the 66 feature genes could effectively classify positive and negative COVID-19 and work as new biomarkers of the disease.

Indexed as

AlgorithmsBiomarkersComputational BiologyCOVID-19COVID-19 TestingFalse Negative ReactionsFalse Positive ReactionsGene Expression ProfilingHumansMachine LearningModels, StatisticalPrincipal Component AnalysisProtein Interaction MappingResearch DesignSensitivity and SpecificityBiomarkers

Identifiers

PMID34603483
PMCPMC8485143
OpenAlexW3202610744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.